Flow Induced Dispersion Analysis (FIDA) is a new revolutionary technology making it possible for you to both improve drug safety and speed up your drug approval processes.

This new proprietary technology is developed for quantification and characterization of proteins (including biologics) and particles up to 1.000 nm diameter, including complex interactions, stoichiometry, oligomeric states etc.

 The FIDA technology is characterized by:

• Being fast (minutes)
• Requiring very small sample amounts (nl-μl)
• Being exceptionally tolerant to the sample matrix.

Contrary to most other procedures, the FIDA methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development is therefore avoided.   

The unique features of FIDA enable characterization and quantification in native (biorelevant) environments. In-built assay quality control ensures high data reliability and walk-away automation sets free resources for other tasks.

The FIDA principle

The FIDA technology is based on dispersion analysis of a parabolic hydrodynamic flow profile. The dispersion of an injected sample zone of an indicator depends on flow channel dimensions, flow rate and apparent diffusivity of the indicator. Dedicated Fidabio instrumentation and software allows accurate quantification of the apparent diffusivity of the indicator in different environments. Particularly, the interaction with an analyte such as an antibody-based drug may be quantified. The principle is illustrated in the figure below.

All patent rights are held by our company, Fida Biosystems ApS.